It's weird the way my life seeps into these investments. I have a real problem with water. It surfaces in many ways but right now my right sink in the bathroom is shut offf by the master valve and the left sink is dripping non stop. It drives me crazy.I t cannot be fixed we have tried twice because I have sunk these sinks into an old chest of drawers creating a unique big mess. It was a good idea 30 years ago. Oppenheimer bullish on Zurn Water Solutions following spinoff 07:38 ZWS
Danger of waiting-! Confluent, Inc. (CFLT) 62.90+3.76 (+6.36%) At close: October 6 4:00PM EDT 64.00+1.10 (+1.75%) Pre-Market:06:18AM EDT
Cytokinetics outlines go-to-market strategy, provides update on pipeline 07:37 CYTK Cytokinetics plans to outline the company's go-to-market strategy for omecamtiv mecarbil in the United States, and present updates on the company's advancing cardiovascular pipeline and strategies. The company also plans to present the clinical trial design for SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy. "Cytokinetics is approaching an inflection point after more than two decades of research and development pioneering the field of muscle biology and advancing the pharmacology of myosin modulators," said Robert Blum, Cytokinetics' President and Chief Executive Officer. "As aficamten advances into Phase 3 with SEQUOIA-HCM, expected to begin this year, our company is well positioned to deliver on the promise of potential medicines for patients with cardiovascular diseases of impaired muscle function and weakness." Go to market; Cytokinetics leadership will outline the go-to-market strategy for omecamtiv mecarbil in the U.S., which will be guided by a build of core capabilities to ensure success based on de-risking milestones leading up to the potential launch of omecamtiv mecarbil. The four pillars of the strategy include first, establishing a deep understanding of patients with worsening heart failure and the healthcare providers and associated institutions who treat this subset of patients. Second, engaging and educating cardiologists who treat these patients and the importance of appropriate treatment. Third, working with payers to ensure affordable access to omecamtiv mecarbil. Finally, supporting patients and caregivers through education, co-pay assistance, and innovative models for patient support. SEQUOIA-HCM: Phase 3 Clinical Trial of Aficamten. Cytokinetics is also presenting the design of SEQUOIA-HCM. SEQUOIA-HCM is a Phase 3l trial designed to evaluate aficamten in patients with symptomatic oHCM on background medical therapy for 24 weeks. The primary objective is to assess the effect of aficamten on change in peak oxygen uptake measured by cardiopulmonary exercise testing from baseline to week 24. Secondary objectives include change in Kansas City Cardiomyopathy Questionnaire score from baseline to week 12 and week 24, the proportion of patients with greater than or equal to1 class improvement in New York Heart Association functional class from baseline to week 12 and week 24, change in post-Valsalva left ventricular outflow tract gradient to week 12 and week 24, the proportion of patients with post-Valsalva LVOT-G less than30 mmHg, and change in total workload during CPET to week 24. SEQUOIA-HCM is planned to enroll 270 patients, randomized on a 1:1 basis to receive aficamten or placebo in addition to standard-of-care treatment. Each patient will receive up to four escalating doses of aficamten or placebo based on echocardiographic guidance alone. Cytokinetics expects to begin SEQUOIA-HCM in Q4 2021.
I've dipped a toe in here plan to add more today: Amicus Therapeutics, Inc. (FOLD)-Plant FOLD In GArden 10.93+0.83 (+8.22%) At close: October 6 4:00PM EDT
BDSI- Strongly Considering) ) ) BioDelivery Sciences International, Inc. (BDSI) 3.7700+0.0700 (+1.89%) At close: October 6 4:00PM EDT
Time To Buy? Pure Storage, Inc. (PSTG) 25.72+0.04 (+0.16%) At close: October 6 4:00PM EDT 26.01+0.29 (+1.13%) Pre-Market:08:00AM EDT